non small-cell lung cancer
Conditions
Interventions
Group 1:Reduction
Group 2:Supportive treatment
Sponsors
The Affiliated Hospital of Inner Mongolia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old; 2. pathological diagnosis of patients with advanced (IIIB/IV) NSCLC; 3. has at least one measurable lesion; 4. Second-line patients who have received a systemic chemotherapy regimen or who have been treated with EGFR-TKI and ALK inhibitors have not detected a driver's gene; 5. ECOG PS score: 0~1 points; 6. Obtain informed consent signed by the patient or his legal representative.
Exclusion criteria
Exclusion criteria: 1. received anti-angiogenic therapy such as bevacizumab within 30 days before second-line treatment; 2. Before the study, the routine blood function of the liver function and abnormal electrocardiogram examination; 3. patients with any signs or history of bleeding physique; 4. symptomatic brain metastasis; 5. small cell lung cancer, including small cell carcinoma and non-small cell carcinoma mixed lung cancer; 6. patients with tumors that have invaded important blood vessels or who are expected to have major bleeding during subsequent studies; 7. have mental illness or can not cooperate with the treatment; 8. breastfeeding or pregnant women; 9. central, cavity lung squamous cell carcinoma, or non-small cell lung cancer patients with hemoptysis (>50mL/day); 10. There are contraindications to chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective response rate;Disease control rate;Quality of Life Score; | — |
Countries
China
Contacts
Public ContactJunzheng Gao
The Affiliated Hospital of Inner Mongolia Medical University
Outcome results
None listed